10.11.2020 • NewsIMCD

IMCD to Buy Peak’s Pharma Business

Dutch specialty chemicals and ingredients distributor IMCD has entered into an agreement to buy the pharmaceutical business of compatriot firm Peak International Products for an undisclosed sum.

Based in Leuvenheim, the Netherlands, Peak distributes APIs for customers in Benelux, Germany, Israel and Vietnam, and generated revenues of about €5.8 million in 2019.

Lodewijk Mellema, managing director IMCD Benelux, commented: ‘With this acquisition IMCD expands its active pharmaceutical ingredients business primarily in Benelux and Vietnam and strengthens our company’s formulation and marketing synergies between active pharmaceutical ingredients and excipients in those regions.”

Peak International’s CEO Erik van den Sigtenhorst added that its existing and future partners will benefit from a significantly increased network within the pharmaceutical industry.

The business to be acquired will be integrated into IMCD Business Group Pharmaceuticals. An expected closing date for the transaction was not revealed.

Earlier this month, IMCD announced that it had successfully completed the acquisition of 70% of Indian specialty chemicals distributor Signet Excipients, with the remaining 30% to follow by 2024.

Signet’s business is focused on the distribution of pharmaceutical, nutraceutical and bio-pharma excipients across categories such as diluents, fillers, sweeteners, disintegrants, binders, surfactants and others. Based in Mumbai, Signet is active in India, Bangladesh, the Middle East and Africa. 

Author: Elaine Burridge, Freelance Journalist

IMCD has agreed to buy the pharmaceutical business of compatriot firm Peak...
IMCD has agreed to buy the pharmaceutical business of compatriot firm Peak International Products for an undisclosed sum. Peak distributes APIs for customers in Benelux, Germany, Israel and Vietnam, and generated revenues of about €5.8 million in 2019. (c) Pexels

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.